Elutia Inc. (ELUT) stock
ELUTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/3011% below fair value
$0.82+0.00 (+0.35%)
Close on Nov 16, 2026Market cap $36.45MP/E –Yield –
Elutia r&d expenses
Research and development expenses are spending on new products and technology.
Elutia's R&D Expenses for the twelve months ending Jun 30, 2026 was $6.80M, up 106.8% year over year. For fiscal 2025 it was $4.16M, up 38.9% from the year before. The highest annual figure on record is $9.27M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.16M | +38.9% |
| FY2024 | Dec 31, 2024 | $3.00M | -31.8% |
| FY2023 | Dec 31, 2023 | $4.40M | -43.1% |
| FY2022 | Dec 31, 2022 | $7.73M | -16.6% |
| FY2021 | Dec 31, 2021 | $9.27M | +55.6% |
| FY2020 | Dec 31, 2020 | $5.95M | +148.1% |
| FY2019 | Dec 31, 2019 | $2.40M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.53M | +155.5% |
| Q1 FY2026 | Mar 31, 2026 | $1.97M | +126.5% |
| Q4 FY2025 | Dec 31, 2025 | $1.22M | +67.1% |
| Q3 FY2025 | Sep 30, 2025 | $1.09M | +55.0% |
| Q2 FY2025 | Jun 30, 2025 | $989.00K | -1.2% |
| Q1 FY2025 | Mar 31, 2025 | $871.00K | -25.7% |
| Q4 FY2024 | Dec 31, 2024 | $727.00K | -47.4% |
| Q3 FY2024 | Sep 30, 2024 | $702.00K | +26.0% |
| Q2 FY2024 | Jun 30, 2024 | $1.00M | +15.2% |
| Q1 FY2024 | Mar 31, 2024 | $1.17M | -26.3% |
| Q4 FY2023 | Dec 31, 2023 | $1.38M | -47.2% |
| Q3 FY2023 | Sep 30, 2023 | $557.00K | -75.5% |
| Q2 FY2023 | Jun 30, 2023 | $869.00K | -74.3% |
| Q1 FY2023 | Mar 31, 2023 | $1.59M | -30.5% |
| Q2 FY2022 | Jun 30, 2022 | $2.62M | +39.1% |
| Q1 FY2022 | Mar 31, 2022 | $2.27M | +32.1% |
| Q4 FY2021 | Dec 31, 2021 | $3.38M | +71.1% |
| Q3 FY2021 | Sep 30, 2021 | $2.29M | +81.1% |
| Q2 FY2021 | Jun 30, 2021 | $1.88M | +33.6% |
| Q1 FY2021 | Mar 31, 2021 | $1.72M | +31.4% |
| Q4 FY2020 | Dec 31, 2020 | $1.97M | +199.8% |
| Q3 FY2020 | Sep 30, 2020 | $1.26M | +149.3% |
| Q2 FY2020 | Jun 30, 2020 | $1.41M | – |
| Q1 FY2020 | Mar 31, 2020 | $1.31M | – |
| Q4 FY2019 | Dec 31, 2019 | $658.00K | – |
| Q3 FY2019 | Sep 30, 2019 | $507.00K | – |
See a number that looks wrong?